Bullish Points: 1. Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on therapeutics for rare genetic diseases of obesity. 2. Their lead product, IMCIVREE (setmelanotide), is approved in the United States for chronic weight management in patients with obesity due to POMC, PCSK1, or LEPR deficiency. 3. The company is also developing setmelanotide for the treatment of additional rare genetic diseases of obesity, including Alström syndrome, Bardet-Biedl syndrome, and other syndromic and non-syndromic diseases of obesity. 4. Over 425 prescriptions for IMCIVREE for BBS were written in the US from FDA approval through June 30, 2023. 5. FDA granted setmelanotide Breakthrough Therapy designation for the treatment of obesity associated with genetic defects upstream of t
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.